IL273648B2 - Microbiota sequence variants of tumor-related antigenic epitopes - Google Patents
Microbiota sequence variants of tumor-related antigenic epitopesInfo
- Publication number
- IL273648B2 IL273648B2 IL273648A IL27364820A IL273648B2 IL 273648 B2 IL273648 B2 IL 273648B2 IL 273648 A IL273648 A IL 273648A IL 27364820 A IL27364820 A IL 27364820A IL 273648 B2 IL273648 B2 IL 273648B2
- Authority
- IL
- Israel
- Prior art keywords
- sequence
- gut microbiota
- tumor
- sequence variant
- variant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001119—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B45/00—ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/075683 WO2018065628A2 (en) | 2016-10-07 | 2017-10-09 | Microbiota sequence variants of tumor-related antigenic epitopes |
| EP17195520 | 2017-10-09 | ||
| EP18305442 | 2018-04-11 | ||
| PCT/EP2018/077515 WO2019072871A2 (en) | 2017-10-09 | 2018-10-09 | MICROBIOTIC SEQUENCE VARIANTS OF ANTIGENIC EPITOPES ASSOCIATED WITH A TUMOR |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL273648A IL273648A (en) | 2020-05-31 |
| IL273648B1 IL273648B1 (en) | 2024-08-01 |
| IL273648B2 true IL273648B2 (en) | 2024-12-01 |
Family
ID=66100441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273648A IL273648B2 (en) | 2017-10-09 | 2018-10-09 | Microbiota sequence variants of tumor-related antigenic epitopes |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200256877A1 (enExample) |
| EP (1) | EP3694541A2 (enExample) |
| JP (1) | JP7232825B2 (enExample) |
| KR (1) | KR102823291B1 (enExample) |
| CN (1) | CN111201032B (enExample) |
| AU (1) | AU2018348432B2 (enExample) |
| CA (1) | CA3075363A1 (enExample) |
| IL (1) | IL273648B2 (enExample) |
| WO (1) | WO2019072871A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102622188B1 (ko) | 2016-10-07 | 2024-01-05 | 엔터롬 에스.에이. | 암 치료를 위한 면역원성 화합물 |
| CN110049774A (zh) | 2016-10-07 | 2019-07-23 | 恩特罗姆公司 | 肿瘤相关抗原表位的小型生物群序列变体 |
| CN117801069A (zh) | 2016-10-07 | 2024-04-02 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
| FI3773689T3 (fi) * | 2018-04-11 | 2023-01-31 | Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon | |
| EP3773673A2 (en) * | 2018-04-11 | 2021-02-17 | Enterome S.A. | Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation |
| WO2021074389A1 (en) * | 2019-10-16 | 2021-04-22 | Enterome S.A. | Immunogenic compounds for treatment of adrenal cancer |
| SI4021487T1 (sl) * | 2019-11-15 | 2024-03-29 | Enterome S.A., | Antigenski peptidi za preprečevanje in zdravljenje b-celične malignosti |
| CN112481299A (zh) * | 2020-11-20 | 2021-03-12 | 郑州大学 | 用于调节PD-1/PD-L1通路的RNAi表达质粒 |
| WO2023244997A1 (en) * | 2022-06-13 | 2023-12-21 | The University Of North Carolina At Chapel Hill | Compositions and methods for inducing anticancer immunity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| CN101835792B (zh) * | 2007-08-20 | 2015-04-15 | 肿瘤疗法科学股份有限公司 | Foxm1肽和包含foxm1肽的药剂 |
| DK2119726T5 (en) | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| WO2011140284A2 (en) * | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| EP2608799B1 (en) * | 2010-08-24 | 2018-12-12 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
| CA2904389C (en) | 2013-03-14 | 2018-09-18 | Jerome J. Schentag | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
-
2018
- 2018-10-09 EP EP18782459.4A patent/EP3694541A2/en active Pending
- 2018-10-09 KR KR1020207013061A patent/KR102823291B1/ko active Active
- 2018-10-09 WO PCT/EP2018/077515 patent/WO2019072871A2/en not_active Ceased
- 2018-10-09 US US16/753,657 patent/US20200256877A1/en active Pending
- 2018-10-09 IL IL273648A patent/IL273648B2/en unknown
- 2018-10-09 AU AU2018348432A patent/AU2018348432B2/en active Active
- 2018-10-09 CA CA3075363A patent/CA3075363A1/en active Pending
- 2018-10-09 JP JP2020518541A patent/JP7232825B2/ja active Active
- 2018-10-09 CN CN201880065726.XA patent/CN111201032B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111201032B (zh) | 2024-05-31 |
| JP2021508313A (ja) | 2021-03-04 |
| IL273648B1 (en) | 2024-08-01 |
| IL273648A (en) | 2020-05-31 |
| JP7232825B2 (ja) | 2023-03-03 |
| AU2018348432A1 (en) | 2020-04-02 |
| WO2019072871A3 (en) | 2019-06-06 |
| CN111201032A (zh) | 2020-05-26 |
| AU2018348432B2 (en) | 2025-08-28 |
| US20200256877A1 (en) | 2020-08-13 |
| CA3075363A1 (en) | 2019-04-18 |
| KR102823291B1 (ko) | 2025-06-19 |
| WO2019072871A2 (en) | 2019-04-18 |
| EP3694541A2 (en) | 2020-08-19 |
| KR20200067862A (ko) | 2020-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273648B2 (en) | Microbiota sequence variants of tumor-related antigenic epitopes | |
| JP2021508313A5 (enExample) | ||
| ES2562157T3 (es) | Vacuna multiepitópica contra los cánceres asociados con Her2/neu | |
| CA2297786A1 (en) | New immunoprotective influenza antigen and its use in vaccination | |
| RU2006127314A (ru) | Вакцина, стимулирующая рост, основанная на нейтрализующем эпитопе | |
| CY1113153T1 (el) | ΙL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ | |
| RU2016133598A (ru) | Композиция микобактериального антигена | |
| Vadesilho et al. | Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC | |
| Fried et al. | Mass spectrometric analysis of Plasmodium falciparum erythrocyte membrane protein‐1 variants expressed by placental malaria parasites | |
| ATE470673T1 (de) | Impfstoffe mit lawsoniaintrazellularis- untereinheit | |
| Kumar et al. | Outer membrane protein assembly factor YaeT (omp85) and GroEL proteins of Edwardsiella tarda are immunogenic antigens for Labeo rohita (Hamilton) | |
| DE602004024423D1 (de) | Impfstoff mit lawsonia intracellularis-untereinheit | |
| JPWO2020071554A5 (enExample) | ||
| CA2542104A1 (en) | Method for the identification of epitopes related to immunogenicity in biopharmaceuticals | |
| ATE342511T1 (de) | Methode zur in vivo identifizierung von intrazellularen epitopen | |
| CN102775486B (zh) | 监测肾损伤的新型试剂和试剂盒 | |
| CN106397549A (zh) | MERS‑CoV特异性多肽及其应用 | |
| Ramalingam et al. | Cloning, expression, and purification of the 27 kDa (MPT51, Rv3803c) protein of Mycobacterium tuberculosis | |
| Singh et al. | Molecular characterization and computational analysis of the major outer membrane protein (ompH) gene of Pasteurella multocida P52 | |
| CN109669043B (zh) | 一种mhc i结合多肽基序的鉴定方法 | |
| WO2009094006A3 (en) | Bordetella outer-membrane protein antigens and methods of making and using the same | |
| DE60025522D1 (de) | Mycoplasma mycoides subsp. mycoides sc antigenisches lppq protein, seine herstellung und verwendung | |
| Cho et al. | Definition of purified enzyme-linked immunosorbent assay antigens from the culture filtrate protein of Mycobacterium bovis by proteomic analysis | |
| Piras et al. | Peptidomics in veterinary science: focus on bovine paratuberculosis | |
| WO2004056316A3 (en) | Vaccines against hiv-1 tat protein to generate neutralizing antibodies |